- Signed a letter of intent for technology export with TCT Health Technologies, a venture capital investment fund in Türkiye
- Major topics have been discussed... Agreement to sign a technology transfer contract in March 2025[by Lee, Young Sung] GI CELL, a GI Innovation affiliate and a research and development company for immune cell therapy, today announced that it signed MOU to export NK cell therapy technology with TCT Health Technologies (hereinafter referred to as TCT), a venture capital investment fund company in Türkiye.The two companies plan to complete the definitive agreement for the out-licensing and tech transfer in March 2025, and through this cooperation, the possibility of NK cell therapy, which is in the spotlight as a next-generation of cell therapy, is expected to be announced widely.The two companies have concluded key term-sheet discussions and agreed to sign a technology transfer contract in January 2025. Pursuant to the contract, TCT will have the right to commercialize T.O.P. NK (allogeneic NK cell therapy) in Türkiye and neighboring countries (Commonwealth of Independent States). TCT is responsible for all development and clinical trials. GI CELL will receive a royalty in the double digits on net sales with no obligation to refund.T.O.P. NK is an allogeneic (off-the-shelf) NK cell therapy derived from healthy donors. The limitation of allogeneic NK cells was that immune cells were exhausted and lost their activity during the culture process. But T.O.P. NK is “fresh” NK cell therapy developed with GI CELL’s proprietary mass culture technology. Phase 1 has already been successfully completed, and Phase 2a clinical trials are in progress for patients with solid cancer and blood cancer in Korea.TCT is a company developing cell and gene therapy. This MOU was led by Dr. Adil Mardinoglu, who is the world-renowned scientist, professor of King’s College London (UK), and current Chief Scientific Officer of TCT.GI CELL and TCT will continue their close collaboration by further discussing additional pipelines and technologies in immune cell therapy.Türkiye has embraced cell therapies as a national strategy. Its already-established GMP facilities underscore Türkiye’s commitment to advancing this field. Along with Japan, it is one of the countries where stem cell therapy is allowed. GI CELL and TCT will continue their close collaboration by further discussing additional pipelines and technologies in immune cell therapy.“We are pleased that GI CELL’s groundbreaking T.O.P. NK has achieved recognition for its scalability as a proprietary platform. As many companies around the world have already expressed interest, we will use this opportunity as a bridgehead to take the lead position as a global NK cell platform company,” said Myoung Ho Jang, Chief Scientific Adviser at GI CELL.link: https://www.thebionews.net/news/articleView.html?idxno=10780
|
ENG